Evidence map›Paper›PMID 42088492›Full record

ArticleFrontiers in immunology2026

Evaluation of dnDSA risk stratification using the updated PIRCHE-T2 model in two kidney transplant cohorts.

Yuan Tian, Matthias Niemann, Benedict M Matern, Lukas Frischknecht, Anna Mallone, Fabian Rössler, Thomas Schachtner, Stefan Schaub, Jakob Nilsson

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuan TianDepartment of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland.
Matthias NiemannResearch and Development, PIRCHE AG, Berlin, Germany.
Benedict M MaternResearch and Development, PIRCHE AG, Berlin, Germany.
Lukas FrischknechtDepartment of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland.
Anna MalloneDepartment of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland.
Fabian RösslerDepartment of Surgery and Transplantation, University Hospital Zurich, Zurich, Switzerland.
Thomas SchachtnerDivision of Nephrology, University Hospital Zurich, Zurich, Switzerland.
Stefan SchaubClinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland.
Jakob NilssonDepartment of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Development of Methods: We compared the predictive performance of the previous and updated PIRCHE-T2 models in two independent kidney transplant cohorts from Zurich (n = 1194) and Basel (n = 387). PIRCHE-T2 scores were assessed at total and locus-specific levels and analyzed in relation to dnDSA incidence using ROC curves, Kaplan-Meier, and Cox regression models. Results: The updated PIRCHE-T2 model generated lower and more condensed scores but improved dnDSA risk stratification across both cohorts. Higher scores remained associated with increased dnDSA risk. Notable improvements were observed for HLA-C scores. HLA-DQ also showed enhanced performance in one-mismatch subgroups and Cox models, while HLA-A improvements were primarily seen in the Basel cohort. Results for other loci remained similar between models, although HLA-DRB1 showed cohort-specific variation, highlighting the need for context-specific threshold refinement. Conclusion: Our findings demonstrate that the updated PIRCHE-T2 model refines immunological risk stratification in kidney transplantation, offering improved performance for certain loci and patient subgroups. Its application may support more precise donor selection and individualized immunological assessment. Given observed cohort-specific differences, future work should focus on optimizing thresholds and validating the model across diverse populations to ensure broader clinical applicability.

Indexed as

Graft RejectionHLA AntigensIsoantibodiesKidney TransplantationAdultCohort StudiesFemaleHumansMaleMiddle AgedRisk AssessmentRisk FactorsTissue DonorsHLA AntigensIsoantibodiesalloimmunitydonor specific antibodieskidney transplantationPIRCHErisk stratification

Identifiers

PMID42088492
PMCPMC13135921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.